BIOMARIN PHARMACEUTICAL
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.
BIOMARIN PHARMACEUTICAL
Industry:
Biotechnology Developer Platform
Founded:
1997-03-01
Address:
San Rafael, California, United States
Country:
United States
Website Url:
http://www.biomarin.com
Total Employee:
1001+
Status:
Active
Contact:
415-506-6700
Total Funding:
585.8 M USD
Technology used in webpage:
IPhone / Mobile Compatible SPF SSL By Default Domain Not Resolving Mobile Non Scaleable Content Nginx Amazon IPv6 JsDelivr Microsoft Azure DNS
Current Advisors List
Board_member
Board_member
Board_member
Current Employees Featured
Chieze Ibeneche-Nnewihe Director, Business Development and Corporate Strategy @ BioMarin Pharmaceutical
Director, Business Development and Corporate Strategy
2020-08-01
Geoff Nichol CMO & SVP, Global Clinical Development @ BioMarin Pharmaceutical
CMO & SVP, Global Clinical Development
2016-11-01
Chris Houlder Head of Global Cybersecurity @ BioMarin Pharmaceutical
Head of Global Cybersecurity
2020-09-01
Kevin Eggan Head of Research and Early Development @ BioMarin Pharmaceutical
Head of Research and Early Development
2020-10-01
Victoria Sluzky Senior VP, Global Quality and Development @ BioMarin Pharmaceutical
Senior VP, Global Quality and Development
2003-02-01
Diane White Exec. Director, Head of Global Project Management @ BioMarin Pharmaceutical
Exec. Director, Head of Global Project Management
2019-10-01
Jean-Jacques Bienaime Chairman of the Board & Chief Executive Officer @ BioMarin Pharmaceutical
Chairman of the Board & Chief Executive Officer
2005-05-01
Brinda Balakrishnan Group Vice President, Corporate and Business Development @ BioMarin Pharmaceutical
Group Vice President, Corporate and Business Development
2015-01-01
Nicole Zilveti Development Sciences Operations Sr. Admin @ BioMarin Pharmaceutical
Development Sciences Operations Sr. Admin
2016-06-01
Paul Stanley Senior Director of Facilities @ BioMarin Pharmaceutical
Senior Director of Facilities
2013-10-01
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2014-11-24 | Prosensa | Prosensa acquired by BioMarin Pharmaceutical | 840 M USD |
2013-01-07 | Zacharon Pharmaceuticals | Zacharon Pharmaceuticals acquired by BioMarin Pharmaceutical | N/A |
2010-08-17 | Zystor | Zystor acquired by BioMarin Pharmaceutical | 115 M USD |
2010-02-10 | LEAD Therapeutics | LEAD Therapeutics acquired by BioMarin Pharmaceutical | 97 M USD |
2009-10-26 | Huxley Pharmaceuticals | Huxley Pharmaceuticals acquired by BioMarin Pharmaceutical | N/A |
2002-02-07 | Glyko Biomedical | Glyko Biomedical acquired by BioMarin Pharmaceutical | N/A |
Newest Events participated
Key Employee Changes
Date | New article |
---|---|
2021-10-04 | BioMarin snags Vertex VP as CMO a month after clinical snafu in gene therapy trial |
Official Site Inspections
http://www.biomarin.com Semrush global rank: 1.68 M Semrush visits lastest month: 14.5 K
- Host name: 13.107.246.40
- IP address: 13.107.246.40
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
Biomarin.com lookup results from whois.corporatedomains.com server:
- Domain created: 13th-Aug-2014
- Domain updated: 15th-May-2024
- Domain expires: 2nd-Dec-2029 4 Years, 323 Days left
- Website age: 10 Years, 152 Days
- Registrar Domain ID: 1870947584_DOMAIN_COM-VRSN
- Registrar Url: http://cscdbs.com
- Registrar WHOIS Server: whois.corporatedomains.com
- Registrar Abuse Contact Email: domainabuse@cscglobal.com
- Registrar Abuse Contact Phone: 8887802723
- Name server:
- NS1-38.AZURE-DNS.COM
- NS2-38.AZURE-DNS.NET
- NS3-38.AZURE-DNS.ORG
- NS4-38.AZURE-DNS.INFO
More informations about "BioMarin Pharmaceutical"
About Us | BioMarin
BioMarin RareConnections™ Program Established. Expanding on its decade-long track record of supporting eligible people with rare diseases in gaining access to the company’s medicines, the BioMarin RareConnections program …See details»
BioMarin Leadership Team - BioMarin Corporate
BioMarin Leadership Team. Alexander Hardy. President and Chief Executive Officer. G. Eric Davis. Executive Vice President, Chief Legal Officer. Greg Friberg. Executive Vice President, …See details»
BioMarin Pharmaceutical - Wikipedia
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturi…See details»
BioMarin Pharmaceutical Inc. - Investor Relations
6 days ago At Biomarin Pharmaceutical Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the …See details»
BioMarin Pharmaceutical - The Org
BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. Industries. …See details»
BioMarin Pharmaceutical Inc. - Governance - Governance
The Board of Directors of BioMarin Pharmaceutical Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance …See details»
About Us - BioMarin Europe & Canada
You are about to leave the BioMarin.eu website and will be redirected to BioMarin’s global website owned and operated by our headquarters, BioMarin Pharmaceutical Inc., located in the United States. Please note that the …See details»
BioMarin Pharmaceutical - Crunchbase Company …
BioMarin Pharmaceutical reported record financial results for 2023, with earnings per share (EPS) increasing to US$0.89 from US$0.76 in FY 2022. The company also beat analyst estimates for its first quarter 2024 earnings. However, the …See details»
BioMarin Announces New R&D and Business Development …
Aug 21, 2024 These risks and uncertainties include, among others: Dr. Friberg and Dr. Sabry commencing employment as anticipated; possible complications associated with the …See details»
BioMarin, Canada
BioMarin RareConnections was created to help navigate some of the difficulties associated with serious rare genetic diseases by offering product support services throughout the treatment …See details»
BioMarin Simplifies Organizational Structure to Increase Efficiency
SAN RAFAEL, Calif., Oct. 6, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced its decision to redesign the organization to better focus …See details»
Support for Society | BioMarin
Supporting the communities where we live and work is central to who we are. We provide funding and support for a variety of activities, projects and events focused on patients, the scientific …See details»
BioMarin, Canada
Géré par le partenaire de BioMarin, Innomar Strategies, BioMarin RareConnections est un service privé, confidentiel et gratuit d’assistance aux personnes auxquelles des médicaments …See details»
BioMarin Announces Appointment of Cristin Hubbard as Chief …
Mar 7, 2024 This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements …See details»
BioMarin - Overview, News & Similar companies | ZoomInfo.com
Jun 20, 2024 BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on ... BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that …See details»
BioMarin, having retrenched, outlines plans for growth
Sep 4, 2024 BioMarin aims to bring in $4 billion in revenue by 2027, up from $2.4 billion last year, and maintain an annual growth rate in the mid-teen percentages through the decade, …See details»
Responsibility | BioMarin
As a global corporate citizen, BioMarin strives to operate in ways that contribute to the health of our environment, employees and communities. Learn More. Support for Society We’re …See details»
BioMarin - Overview, News & Similar companies | ZoomInfo.com
Who is BioMarin. BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical …See details»
Community Commitment | BioMarin
This BioMarin program focuses on developing BioMarin employees by providing a more senior BioMarin colleague to serve as a development partner for coaching and advice. Special …See details»
Chief R&D Officer Greg Friberg Discusses Career | BioMarin
Oct 28, 2024 BioMarin has an impressive track record of developing transformational medicines and what has set the company apart is a combination of three qualities: great science, great …See details»